Abstract submission
Abstract submission is now open.
The EMAS 2027 Scientific Committee invites researchers and healthcare professionals from around the world to submit abstracts for review and possible presentation. Please read the guidelines below before you begin.
Submit your abstractTopics
Select a topic area to see its subtopics. Abstracts are invited in the following topics:
1. Menopause and the menopausal transition (16 subtopics)
1.1. Menopausal transition, perimenopause and symptom trajectories
1.2. Vasomotor symptoms and thermoregulation
1.3. Menopausal hormone therapy: efficacy, safety and personalised prescribing
1.4. Non-hormonal pharmacological therapies, including neurokinin-targeted treatments
1.5. Complementary, traditional and integrative approaches
1.6. Nutrition, physical activity and dietary supplements
1.7. Sleep, fatigue and circadian health
1.8. Mood, anxiety and psychological wellbeing
1.9. Cognition and brain health
1.10. Sexual health and female sexual dysfunction
1.11. Genitourinary syndrome of menopause and recurrent urinary tract infection
1.12. Premature ovarian insufficiency, early and surgical menopause
1.13. Cancer treatment-induced menopause and survivorship
1.14. Menopause in the workplace
1.15. Quality of life, patient-reported outcomes and core outcome sets
1.16. Menopause education, health literacy and shared decision-making
2. Gynaecology and women’s health across the life course (13 subtopics)
2.1. Contraception in midlife and the menopausal transition
2.2. Fertility, assisted reproduction and fertility preservation
2.3. Benign gynaecology, including abnormal uterine bleeding
2.4. Pelvic floor health, urogynaecology and urinary incontinence
2.5. Benign breast disease and breast health
2.6. Breast cancer: risk, prevention, treatment effects and survivorship
2.7. Gynaecological cancers: prevention, treatment effects and survivorship
2.8. Endocrinology, androgen excess and androgen insufficiency
2.9. Testosterone and other androgen therapies in women
2.10. Sexual and reproductive health
2.11. Sexual orientation, gender identity and inclusive midlife care
2.12. Pregnancy history and later-life health
2.13. Health inequities, intersectionality and underserved populations
3. Men’s midlife health and ageing (9 subtopics)
3.1. Late-onset hypogonadism: diagnosis and management
3.2. Testosterone therapy and androgen receptor modulators
3.3. Male sexual dysfunction
3.4. Lower urinary tract symptoms and urinary incontinence
3.5. Male reproductive ageing and fertility
3.6. Prostate and other cancers: treatment effects and survivorship
3.7. Cardiometabolic, musculoskeletal and cognitive health in ageing men
3.8. Lifestyle, complementary and integrative approaches
3.9. Couple health and shared midlife transitions
4. Midlife health, healthy ageing and longevity (21 subtopics)
4.1. Cardiovascular health and disease prevention
4.2. Metabolic health, insulin resistance and diabetes
4.3. Obesity, body composition and weight-management therapies
4.4. Bone health, osteoporosis and fracture prevention
4.5. Osteoarthritis, musculoskeletal pain and mobility
4.6. Sarcopenia, frailty and physical function
4.7. Dementia, cognition and brain-health prevention
4.8. Neurological disorders, migraine and sensory health
4.9. Depression, anxiety and severe mental illness
4.10. Sleep disorders and circadian health
4.11. Nutrition, physical activity and behavioural medicine
4.12. Multimorbidity, polypharmacy and deprescribing
4.13. Immunity, inflammation and autoimmune disease
4.14. Skin, hair and connective-tissue ageing
4.15. Healthy longevity, biological ageing and geroscience
4.16. Life-course predictors and prevention of later-life disease
4.17. Screening, risk assessment and prevention
4.18. Epidemiology, population health and real-world evidence
4.19. Cross-cultural, socioeconomic and geographic differences
4.20. Occupational health, unpaid care and social participation
4.21. Climate, environmental exposures and midlife health
5. Innovation, implementation and models of care (18 subtopics)
5.1. Artificial intelligence, machine learning and clinical decision support
5.2. Digital health, FemTech, mobile health and virtual care
5.3. Wearables, sensors, digital biomarkers and remote monitoring
5.4. Virtual, augmented and immersive technologies
5.5. Precision medicine, biomarkers, genomics and multi-omics
5.6. Basic, translational and systems science
5.7. Diagnostics, imaging and risk-prediction tools
5.8. Drug discovery, novel therapeutics and clinical trials
5.9. Medical devices, minimally invasive treatments and surgery
5.10. Implementation science and evidence-to-practice translation
5.11. Integrated, multidisciplinary and community-based care
5.12. Nursing, pharmacy and allied-health models of care
5.13. Health services research, quality improvement and patient safety
5.14. Health economics, access, reimbursement and policy
5.15. Co-design, patient and public involvement, and citizen science
5.16. Education, training and competency development
5.17. Research methods, outcome measures and open science
5.18. Ethics, equity, privacy and responsible innovation
Presentation formats
Indicate your preferred format when you submit. The Scientific Committee reserves the right to assign the format most appropriate to your abstract.
Case report submissions require informed patient consent, which the authors must obtain and confirm. Please follow the CARE guidelines for case reports.
Submission requirements
Authors
List all authors and affiliations, and identify the presenting author.
Length
Maximum 2,500 characters, including spaces.
Figures and tables
Tables, figures, images and other graphical elements are not permitted.
Accreditation
Abstracts must comply with EACCME® guidelines for accreditation.
The title and body text must not contain brand names, trade names or proprietary product names. If they do, you will be asked to edit the abstract.
Use of generative AI
You must declare any use of generative AI in your abstract text when you submit. Responsible use to support preparation, such as structuring content or improving language, is permitted in line with Elsevier’s guidance for authors. AI tools must not replace clinical judgement or expert interpretation, and they must not be listed as authors or co-authors.
For more information, see Generative AI policies for journals.
Timeline
Presenting authors will be notified of the outcome of their abstract by the end of February 2027.
Publication
All accepted abstracts will be published online on the congress website and in Maturitas, an international, multidisciplinary, peer-reviewed journal of midlife health and beyond. Maturitas has an Impact Factor of 4.2 and a CiteScore of 6.2.
Invited faculty and speakers taking part in society symposia should use the dedicated submission form to submit their presentation abstract.
Early-career researchers
To apply for the New Investigator award, tick the option on the submission form. Eligible presenters must be 35 or younger at the time of the congress and will be asked to provide proof of age. Details of all EMAS awards are on our Awards page.
Find out more about the JuMP programme for junior members of EMAS.
Any questions?
Contact the EMAS Scientific Programme Team at [email protected]